Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF DERMATOLOGY
Volume 53, Issue 3, Pages 376-384
Publisher
Wiley
Online
2013-07-25
DOI
10.1111/ijd.12205
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma
- (2012) Sapna P Patel et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
- (2012) Tudor Ciuleanu et al. LANCET ONCOLOGY
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radiation-Induced Increase in Cell Migration and Metastatic Potential of Cervical Cancer Cells Operates Via the K-Ras Pathway
- (2011) Wen-Hong Su et al. AMERICAN JOURNAL OF PATHOLOGY
- Reacções cutâneas adversas aos inibidores do receptor do factor de crescimento epidérmico: estudo de 14 doentes
- (2011) Felicidade Santiago et al. ANAIS BRASILEIROS DE DERMATOLOGIA
- Meta-analysis of dermatological toxicities associated with sorafenib
- (2011) L. Zhang et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Skin Tumors Induced by Sorafenib; Paradoxic RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1
- (2011) J. P. Arnault et al. CLINICAL CANCER RESEARCH
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib
- (2011) BETH MCLELLAN et al. Dermatologic Therapy
- Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds
- (2011) Ithaisa Sologuren et al. HUMAN MOLECULAR GENETICS
- Sorafenib-induced premalignant and malignant skin lesions
- (2011) Victoria L. Williams et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors
- (2011) Yevgeniy Balagula et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
- (2011) Eve Maubec et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction of Cutaneous Squamous Cell Carcinomas by RAF Inhibitors: Cause for Concern?
- (2011) Mario E. Lacouture et al. JOURNAL OF CLINICAL ONCOLOGY
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies
- (2011) Yevgeniy Balagula et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Disseminated follicular eruption during therapy with the MEK inhibitor AZD6244
- (2011) Christiane Querfeld et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours
- (2010) Ingrid M. E. Desar et al. ACTA ONCOLOGICA
- Refractory aggressive keratoacanthoma centrifugum marginatum of the scalp controlled with the epidermal growth factor receptor inhibitor erlotinib
- (2010) T.K. Bulj et al. BRITISH JOURNAL OF DERMATOLOGY
- Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients
- (2010) B. Nardone et al. CLINICAL CANCER RESEARCH
- Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
- (2010) Yevgeniy Balagula et al. INVESTIGATIONAL NEW DRUGS
- Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’
- (2009) Stefan Boeck et al. ANTI-CANCER DRUGS
- Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
- (2009) W.J. Lee et al. BRITISH JOURNAL OF DERMATOLOGY
- Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib
- (2009) Zita Dubauskas et al. Clinical Genitourinary Cancer
- The histologic spectrum of epithelial neoplasms induced by sorafenib
- (2009) Eun Ji Kwon et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib
- (2009) Adam D. Lipworth et al. ONCOLOGY
- Skin toxicities associated with epidermal growth factor receptor inhibitors
- (2009) Tianhong Li et al. Targeted Oncology
- Skin reactions to the new biologic anticancer drugs
- (2009) Patricia L Myskowski et al. Current Opinion in Supportive and Palliative Care
- Multiple Squamous Cell Carcinomas of the Skin After Therapy With Sorafenib Combined With Tipifarnib
- (2008) David S. Hong et al. ARCHIVES OF DERMATOLOGY
- Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor
- (2008) Julien Autier et al. ARCHIVES OF DERMATOLOGY
- Dermatologic symptoms associated with the multikinase inhibitor sorafenib
- (2008) Caroline Robert et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started